AZD0516
AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer[1].
Product Specifications
UNSPSC
12352211
Target
Antibody-Drug Conjugates (ADCs) ; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
95.82
Smiles
[AZD0516]
References & Citations
[1]1158-Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer. AACR Annual Meeting 2025 Itinerary Planner Home.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LS006637-100ug 100 µg
SNRPG (NM_003096) Human Over-expression Lysate
Sign In for Pricing
View Details 
12586151 3x 1.0 µg DNA
ASTL CRISPR All-in-one AAV vector set (with saCas9)(Human)
Sign In for Pricing
View Details 
OR1050551-01 100 mg
Tert-Butyl 4- (3-chlorophenyl) -4-cyanopiperidine-1-carboxylate
Sign In for Pricing
View Details OR1050551-02 250 mg
Tert-Butyl 4- (3-chlorophenyl) -4-cyanopiperidine-1-carboxylate
Sign In for Pricing
View Details